Eribulin chemotherapy after taxane treatment in advanced metastatic breast cancer
Kashiwagi, S.; Ishihara, S.; Asano, Y.; Kurata, K.; Tauchi, Y.; Tokumoto, M.; Morisaki, T.; Noda, S.; Kawajiri, H.; Takashima, T.; Onoda, N.; Hirakawa, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1951-1953
2014
ISSN/ISBN: 0385-0684 PMID: 25731386 Document Number: 677315
Clinical outcomes, including adverse events, in 52 advanced breast cancer patients treated with eribulin chemotherapy after taxane treatment (TX) were analyzed to confirm the effectiveness and safety of this treatment.The objective response rate (ORR) in patients was 34.6% (TX group 31.6%, non-TX group 36.4%). There were no significant differences in overall survival, time to treatment failure, or progression-free between three TX and non-TX groups. Further, adverse events did not differ between groups expression of neutropenia of Grade 3 or more. On the other hand, the number of patients with sensory peripheral neuropathy of Grade 1 or more was significantly more in the TX group than in the non-TX group. Eribulin chemotherapy was effective for the treatment of advanced breast cancer regardless of a history of taxane treatment.In addition, sensory peripheral neuropathy is a possible complication that can occur in advanced breast cancer patients treated with eribulin chemotherapy with taxane treatment history.